SALT LAKE CITY, May 2 /PRNewswire-FirstCall/ -- Myriad Genetics, Inc. (Nasdaq: MYGN), has arranged a conference call with the management team to provide a company update. Peter Meldrum, President and Chief Executive Officer will host the call along with Jay Moyes, Chief Financial Officer, and Adrian Hobden, Ph.D., President of Myriad Pharmaceuticals, Inc.
DATE: May 4, 2005
TIME: 10:00 a.m. Eastern
DOMESTIC DIAL-IN: (888) 589-2820
INTERNATIONAL DIAL-IN: (706) 634-2173
(Please call in approximately 10 minutes before the call is scheduled to begin.)
A Third Quarter Financial Results press release will be issued at 6:30 a.m. on May 4th. Replay of the call will be available from two hours after the call through May 11th, by dialing (800) 642-1687 or (706) 645-9291.
An audio Web cast of the call will be available through a link on Myriad's home page at http://www.myriad.com.
Myriad Genetics, Inc. is a biopharmaceutical company focused on the development of novel healthcare products. The Company develops and markets predictive medicine products, and is developing and intends to market therapeutic products. Myriad's news and other information are available on the Company's Web site at http://www.myriad.com.
SOURCE Myriad Genetics, Inc.
CONTACT: William A. Hockett, Vice President of Corporate Communications of Myriad Genetics, Inc. +1-801-584-3600, firstname.lastname@example.org
Web site: http://www.myriad.com